Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Neurotrophin level imbalances and altered p75 neurotrophin receptor (p75 NTR) expression are implicated in spinal motor neuron degeneration in human and mouse models of amyotrophic lateral sclerosis (ALS). Recently, elevated reactive astrocyte‐derived nerve growth factor (NGF) was linked to p75 NTR‐expressing motor neuron death in adult transgenic ALS mice. To test the role of NGF‐dependent p75 NTR‐mediated signalling in ALS, we examined the effects of a cyclic decapeptide antagonist of p75 NTR ligand binding by using neurotrophin‐stimulated cell death assays and transgenic ALS mice. Murine motor neuron‐like (NSC‐34) cell cultures expressed full‐length and truncated p75 NTR, tyrosine receptor kinase B (TrkB), and the novel neurotrophin receptor homolog‐2 (NHR2) but were TrkA deficient. Accordingly, treatment of cells with NGF induced dose‐dependent cell death, which was significantly blocked by the cyclic decapeptide p75 NTR antagonist. Application of brain‐derived neurotrophic factor, neurotrophin‐3, or neurotrophin‐4 to cultures increased cell proliferation, and such trophic effects were abolished by pretreatment with the tyrosine kinase inhibitor K‐252a. Systemic administration of a modified cyclic decapeptide p75 NTR antagonist conjugated to the TAT4 cell permeabilization sequence to presymptomatic transgenic SOD1 G93A mice affected neither disease onset nor disease progression, as determined by hindlimb locomotor, grip strength, and survival analyses. These studies suggest that disrupting NGF‐p75 NTR interactions by using this approach is insufficient to alter the disease course in transgenic ALS mice. Thus, alternate ligand‐independent pathways of p75 NTR activation or additional NGF receptor targets may contribute to motor neuron degeneration in ALS mice. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298
Development and characterisation of a glutamate-sensitive motor neurone cell line
Eggett, C. J., Crosier, S., Manning, P., Cookson, M. R., Menzies, F. M., McNeil, C. J., & Shaw, P. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741895.x · Cited by 111
Cited by
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
“In fact an antagonist for p75NTR has been shown to slow ALS progression in SOD1 mice (Turner et al., 2004).”
BackgroundTransgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS
TURNER, B., & TALBOT, K. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.01.001 · Cited by 496
Self-citationLost in translation: Treatment trials in the SOD1 mouse and in human ALS
Benatar, M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.015 · Cited by 350
The Recent Understanding of the Neurotrophin’s Role in Skeletal Muscle Adaptation
Sakuma, K., & Yamaguchi, A. (2011) · BioMed Research International · doi:10.1155/2011/201696 · Cited by 120
“Systemic administration of a modified cyclic decapeptide p75NTR antagonist conjugated to the TAT4 cell permeabilization sequence to presymptomatic transgenic SOD1G93A mice affected neither disease onset nor disease progression, as determined by hindlimb locomotion, grip strength, and survival [102].”
BackgroundCharacterization and use of the NSC-34 cell line for study of neurotrophin receptor trafficking
Matusica, D., Fenech, M. P., Rogers, M., & Rush, R. A. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21507 · Cited by 67
“…hr of 55–60% at 200ng/ml of NGF in NSC-34D occurred, but not in NSC-34 cells, supporting a previous report that NSC-34D cells lack the TrkA receptor (Turner et al., 2004) typical of motor neurons but expresses biologically active and functional p75NTR receptor, which may be involved in mediating…”
BackgroundInfluential
Metadata
- Authors
- Turner, B. J., Murray, S. S., Piccenna, L. G., Lopes, E. C., Kilpatrick, T. J., & Cheema, S. S.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2004-08-30
- Volume
- 78
- Issue
- 2
- Pages
- 193-199
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2087707520
- Cited by
- 54
- References
- 2
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. https://app.cochat.ai/papers/10.1002/jnr.20256
- The paper
- Turner, B. J., Murray, S. S., Piccenna, L. G., Lopes, E. C., Kilpatrick, T. J., & Cheema, S. S. (2004). Effect of p75 neurotrophin receptor antagonist on disease progression in transgenic amyotrophic lateral sclerosis mice. Journal of Neuroscience Research. https://doi.org/10.1002/jnr.20256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.